Antitumor effect of Deoxypodophyllotoxin on human breast cancer xenograft transplanted in BALB/c nude mice model

被引:15
作者
Khaled, Meyada [1 ]
Belaaloui, Ghania [2 ]
Jiang, Zhen-Zhou [3 ,4 ]
Zhu, Xiong [5 ]
Zhang, Lu-Yong [3 ]
机构
[1] Batna 2 Univ, Fac Life & Nat Sci, Fesdis 05000, Batna, Algeria
[2] Batna 2 Univ, Dept Med, Fac Med, Ezzouhour 05000, Batna, Algeria
[3] China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China
[4] China Pharmaceut Univ, Jiangsu Ctr Pharmacodynam Res & Evaluat, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China
[5] China Pharmaceut Univ, Med & Chem Inst, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
DPT-beta-CD; MDA-MB-231; Breast cancer; Nude mice; VP-16; Docetaxel; BETA-CD; DOCETAXEL; ETOPOSIDE; APOPTOSIS;
D O I
10.1016/j.jiac.2016.07.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Recently, biologically active compounds isolated from plants used in herbal medicine have been the center of interest. Deoxypodophyllotoxin (DPT), structurally closely related to the lignan podophyllotoxin, was found to be a potent antitumor and antiproliferative agent, in several tumor cells, in vitro. However, DPT has not been used clinically yet because of the lack of in vivo studies. This study is the first report demonstrating the antitumor effect of DPT on MDA-MB-231 human breast cancer xenografts in nude mice. DPT, significantly, inhibited the growth of MDA-MB-231 xenograft in BALB/c nude mice. The TIC value (the value of the relative tumor volume of treatment group compared to the control group) of groups treated with 5, 10, and 20 mg/kg of intravenous DPT-HP-beta-CD was 42.87%, 34.04% and 9.63%, respectively, suggesting the positive antitumor activity of DPT. In addition, the antitumor effect of DPT-HP-beta-CD (20 mg/kg) in human breast cancer MDA-MB-231 xenograft was more effective than etoposide (VP-16) (20 mg/kg) and docetaxel (20 mg/kg). These findings suggest that this drug is a promising chemotherapy candidate against human breast carcinoma. (C) 2016 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:692 / 696
页数:5
相关论文
共 20 条
  • [1] AISNER J, 1991, CANCER, V67, P215, DOI 10.1002/1097-0142(19910101)67:1+<215::AID-CNCR2820671302>3.0.CO
  • [2] 2-D
  • [3] Benzina S, 2015, ANTI-CANCER AGENT ME, V15, P79
  • [4] 2ND-LINE CHEMOTHERAPY WITH LONG-TERM LOW-DOSE ORAL ETOPOSIDE IN PATIENTS WITH ADVANCED BREAST-CANCER
    BONTENBAL, M
    PLANTING, AST
    VERWEIJ, J
    DEWIT, R
    KRUIT, WHJ
    STOTER, G
    KLIJN, JGM
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1995, 34 (02) : 185 - 189
  • [5] Ferlay J., 2013, IARC CancerBase
  • [6] GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1
  • [7] 2-hydroxypropyl-β-cyclodextrin (HP-β-CD):: A toxicology review
    Gould, S
    Scott, RC
    [J]. FOOD AND CHEMICAL TOXICOLOGY, 2005, 43 (10) : 1451 - 1459
  • [8] Deoxypodophyllotoxin: A promising therapeutic agent from herbal medicine
    Khaled, Meyada
    Jiang, Zhen-Zhou
    Zhang, Lu-Yong
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2013, 149 (01) : 24 - 34
  • [9] Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer
    Kouroussis, C
    Androulakis, N
    Kakolyris, S
    Souglakos, J
    Kotsakis, T
    Mavroudis, D
    Katsogridakis, K
    Vardakis, N
    Hatzidaki, D
    Samonis, G
    Vlachonikolis, J
    Georgoulias, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 862 - 869
  • [10] Luo HW, 2012, United States patent, Patent No. [US 10823054,1, 108230541]